Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Nasal Balloon Autoinflation as a First Line Treatment for Glue Ear That Could Improve the Lives of Children With Hearing Loss and Reduce Grommet Surgery


News provided by

Kestrel Medical Ltd

14 Mar, 2016, 17:30 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Otovent(R) Glue Ear Treatment ( www.gluear.co.uk ) (PRNewsFoto/Kestrel Medical) (PRNewsFoto/Kestrel Medical)
This image opens in the lightbox
Otovent(R) is suitable for adults and children from 3 years of age (PRNewsFoto/Kestrel Medical) (PRNewsFoto/Kestrel Medical)

BROADSTONE, England, March 14, 2016 /PRNewswire/ --

An auto inflation device could be used as a first-line non-surgical, drug-free treatment option for glue ear according to a new report published by the National Institute for Health and Care Excellence.

     (Video: https://www.youtube.com/watch?v=Bwh5IyN26Fk )

     (Logo: http://photos.prnewswire.com/prnh/20160314/343863LOGO )

     (Photo: http://photos.prnewswire.com/prnh/20160314/343864 )

Otovent, from Kestrel Medical, offers a non-invasive alternative to antibiotics and surgery for the 80% of children in the UK that suffer with Otitis Media with Effusion[1] and should be used as a first-line treatment during or after the period of active observation following diagnosis, according to the report. Otovent works by using pressure from a balloon to help drain fluid that gets trapped in the middle ear and causes subsequent hearing problems.

As pointed out by the specialist commentators, parents are often disheartened when told to wait for 3 months to see if the symptoms of glue ear improve. They are therefore keen to try this treatment as it may reduce the need for grommet surgery and does not require a high level of monitoring compared to hearing aids. Otovent will also allow parents to initially treat children in the home environment, without having to rely on antibiotics or surgery.

According to the report, Otovent can easily be incorporated into NHS clinics, along with information on the effectiveness and instruction on the method. If no clinician is available to show how to use the device correctly, there are a number of instructional videos available on the internet.

The report reviews four randomised clinical trials on Otovent involving a total of 565 children. All trials showed statistically significant improvements in middle ear function with Otovent compared with standard care. The improvements were determined by pneumatic optometry and tympanometry. No serious adverse effects associated with using the Otovent balloon were reported.

The latest trial of 320 children aged 4 to 11 years, undertaken by Dr Williamson at the University of Southampton, found that children using Otovent experienced fewer days with any glue-ear related symptoms compared to those that didn't at both one (47.3% and 35.6%, respectively) and three months (49.6% and 38.3%, respectively). Otovent also produced greater improvements in ear-related quality of life assessed using the validated tool, a 14-point questionnaire on the impact of OME (OMQ-14).

In 2013-2014 there were 22,809 operations for the insertion of grommets, at an average cost of £802 per operation[2]. Treating patients with Otovent during the initial period of observation does not involve additional costs of monitoring. It is therefore suggested that Otovent might reduce costs to the NHS by reducing the need for surgical intervention. Additionally, to introduce Otovent as a first-line treatment in the care pathway, no changes would be needed in the organisation or delivery of current services and no other facilities or technologies would be needed.

Otitis Media with Effusion, commonly known as Glue Ear, is a widespread condition that affects around 200,000 children every year in the UK and is most common in children under the age of ten[3]. It's caused when a sticky, glue-like fluid fills the middle ear and causes the child to have problems hearing. Ongoing hearing loss or pain often results in a grommet operation, which is the most common reason for general anaesthetic in children.

For further information, contact Kestrel Medical on +44-(0)1202-658444.

About Otovent  

Otovent is a proven effective form of treatment for reducing the symptoms of glue ear (Otitis Media with Effusion). It is the only clinically effective, non-surgical and drug free treatment for glue ear.

Otovent is a small balloon which the child inflates through their nose. The act of blowing up the balloon helps to open up the Eustachian tube, making it easier for fluid to drain from the middle ear. The Otovent balloon equalises the pressure to relieve the symptoms in the middle ear.

--------------------------------------------------

1. http://www.nhs.uk

2. Department of Health 2015

3. Zeilhuis

Otovent needs to be used three times a day until all the fluid has drained away. Results can often be seen as early as a few days into using it.

Link to the report (published on 15th March 2015): https://www.nice.org.uk/advice/mib59

Link to the Williamson et al. (2015) study: http://www.cmaj.ca/content/early/2015/07/27/cmaj.141608.full.pdf+html

Press enquiries: George Ponsford +44(0)1202-658-444
Email: George@kestrelmedical.co.uk / luke@kestrelmedical.co.uk

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.